Pancreatic Cancer Update, Issue 1, 2019


Interview with Andrew H Ko, MD

Track 1: Case: A 45-year-old woman with borderline resectable adenocarcinoma of the pancreas attains an excellent response to neoadjuvant FOLFIRINOX
Track 2: Role of genetic counseling and molecular profiling for patients with pancreatic cancer
Track 3: Effects of mutational load and PD-L1 expression on response to immunotherapy
Track 4: Pathophysiology of pancreatic cancer
Track 5: Radiographic criteria for defining resectable versus borderline resectable disease and implications for therapy
Track 6: Response and tolerability with neoadjuvant FOLFIRINOX
Track 7: Ongoing Phase II SWOG-S1505 trial of perioperative modified FOLFIRINOX (mFOLFIRINOX) versus gemcitabine/nab paclitaxel for resectable adenocarcinoma of the pancreas
Track 8: Efficacy of neoadjuvant chemotherapy for patients with resectable pancreatic cancer
Track 9: Case: A 78-year-old man with resected pancreatic cancer treated with adjuvant single-agent gemcitabine
Track 10: Risk of recurrence for patients with resectable pancreatic cancer
Track 11: Results from the Phase III PRODIGE 24/CCTG PA.6 trial evaluating adjuvant mFOLFIRINOX versus gemcitabine for patients with resected pancreatic ductal adenocarcinoma
Track 12: Risks and benefits with nab paclitaxel/gemcitabine and FOLFIRINOX as adjuvant therapy
Track 13: Case: A 70-year-old man with metastatic adenocarcinoma of the pancreas develops severe peripheral neuropathy with gemcitabine/nab paclitaxel as first-line therapy
Track 14: Peripheral neuropathy associated with nab paclitaxel
Track 15: Approach to first-line therapy for metastatic pancreatic cancer
Track 16: Combination immunotherapeutic approaches under investigation for advanced pancreatic cancer
Track 17: Efficacy and tolerability of the pegylated recombinant human hyaluronidase enzyme PEGPH20 in patients with advanced pancreatic cancer
Track 18: Therapeutic options for patients with metastatic pancreatic cancer and disease progression on gemcitabine/nab paclitaxel
Track 19: NAPOLI-1: Results of a Phase III trial of nanoliposomal irinotecan (nal-IRI) and 5-FU/leucovorin (LV) for metastatic pancreatic cancer after gemcitabine-based therapy
Track 20: Palliative care for patients with metastatic pancreatic cancer
Track 21: Case: A 54-year-old woman with locally advanced pancreatic cancer and refractory ascites
Track 22: Case: A 53-year-old man of Ashkenazi Jewish descent with a strong family history of BRCA mutation-associated cancers presents with metastatic pancreatic cancer and is found to harbor a germline BRCA2 mutation
Track 23: Case: A 62-year-old woman with pancreatic cancer and a solitary liver lesion receives FOLFIRINOX followed by stereotactic body radiation therapy

Interview with E Gabriela Chiorean, MD

Track 1: Biomarker-driven and molecular-targeted therapies for patients with adenocarcinoma of the pancreas
Track 2: Rationale for the investigation of PEGPH20 in combination with pembrolizumab for previously treated hyaluronic acid (HA)-high metastatic pancreatic cancer
Track 3: Tolerability and quality of life with PEGPH20 in combination with chemotherapy; mitigation of associated thromboembolic events
Track 4: Ongoing Phase II trial of PEGPH20 with pembrolizumab for previously treated HA-high metastatic pancreatic ductal adenocarcinoma
Track 5: Testing for emerging biomarkers (eg, microsatellite instability) of response to immune checkpoint inhibitors in metastatic pancreatic cancer
Track 6: Incidence of germline BRCA mutations and response to PARP inhibition
Track 7: Case: A 55-year-old woman presents with back pain and dyspepsia and is diagnosed with borderline resectable adenocarcinoma of the pancreas
Track 8: Risk of relapse with and without adjuvant chemotherapy for patients with lymph node involvement
Track 9: Clinical experience with adjuvant FOLFIRINOX and gemcitabine/nab paclitaxel
Track 10: Activity, tolerability and dosing of adjuvant FOLFIRINOX
Track 11: Role of neoadjuvant chemotherapy in the treatment of resectable or borderline resectable adenocarcinoma of the pancreas
Track 12: Case: A 69-year-old woman with metastatic pancreatic cancer receives nal-IRI/5-FU/LV after experiencing disease progression on gemcitabine/nab paclitaxel
Track 13: Response and tolerability with FOLFIRINOX compared to gemcitabine/nab paclitaxel
Track 14: Second-line therapy options for metastatic pancreatic cancer
Track 15: SWOG-S1513: An ongoing Phase II trial evaluating FOLFIRI alone versus modified FOLFIRI with the PARP inhibitor veliparib as second-line therapy for metastatic pancreatic cancer
Track 16: Investigation of CDK4/6 inhibition-based therapies for advanced pancreatic cancer
Track 17: Second opinion: A 53-year-old man of Ashkenazi Jewish descent with a strong family history of BRCA mutation-associated cancers presents with metastatic pancreatic cancer and is found to harbor a germline BRCA2 mutation
Track 18: Importance of palliative care in managing the symptoms of pancreatic cancer
 
FACULTY
 
Andrew H Ko, MD
Professor, Division of Hematology/Oncology
Gastrointestinal Oncology Program
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California
 
E Gabriela Chiorean, MD
Professor of Medicine
Medical Oncology
University of Washington
Associate Member
Clinical Research Division
Fred Hutchinson Cancer Research Center
Director, Clinical Research
GI Oncology Program
University of Washington/Fred Hutchinson
Cancer Research Center/Seattle Cancer Care Alliance
Clinical Director
GI Medical Oncology
Seattle Cancer Care Alliance
Seattle, Washington
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida